Asterias Biotherapeutics Inc (AST) Set to Announce Quarterly Earnings on Monday

Asterias Biotherapeutics Inc (NYSE:AST) will be announcing its earnings results after the market closes on Monday, November 13th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter.

Asterias Biotherapeutics (NYSE:AST) last posted its earnings results on Monday, August 14th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.18). Asterias Biotherapeutics had a negative return on equity of 86.25% and a negative net margin of 2,762.03%. The business had revenue of $0.32 million during the quarter, compared to analysts’ expectations of $1.25 million.

Shares of Asterias Biotherapeutics Inc (NYSE:AST) opened at $2.35 on Friday. Asterias Biotherapeutics Inc has a 52 week low of $2.25 and a 52 week high of $5.80.

Several equities analysts have recently weighed in on AST shares. Zacks Investment Research raised shares of Asterias Biotherapeutics from a “hold” rating to a “buy” rating and set a $4.00 price target for the company in a research note on Monday, July 17th. HC Wainwright set a $12.00 price target on shares of Asterias Biotherapeutics and gave the stock a “buy” rating in a research note on Wednesday, July 19th.

A hedge fund recently raised its stake in Asterias Biotherapeutics stock. California State Teachers Retirement System lifted its position in Asterias Biotherapeutics Inc (NYSE:AST) by 4.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 47,764 shares of the biotechnology company’s stock after buying an additional 2,100 shares during the quarter. California State Teachers Retirement System owned about 0.10% of Asterias Biotherapeutics worth $170,000 as of its most recent SEC filing.

ILLEGAL ACTIVITY WARNING: “Asterias Biotherapeutics Inc (AST) Set to Announce Quarterly Earnings on Monday” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with's FREE daily email newsletter.

Leave a Reply